By Chris Wack
Shares of BioXcel Therapeutics rose after the company said it has reached 33% enrollment in a trial of a treatment for agitation associated with bipolar disorders or schizophrenia.
The biopharmaceutical company's stock was up 13%, to $3.10, midday Friday. The shares hit its 52-week low of $1.72 on Feb. 27, and are down 94% in the past 12 months.
BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential supplemental new drug application submission to expand the label of the Food and Drug Administration-approved Igalmi sublingual film.
The New Haven, Conn., company's at-home trial currently has 67 patients enrolled, with 23 clinical trial sites open.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 07, 2025 14:09 ET (19:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。